Andere talen Arcus Biosciences, Inc.

Aandelen

RCUS

US03969F1093

Biotechnologie & Medisch Onderzoek

Beurs gesloten - Nyse Andere beurzen 22:00:02 12-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
21,53 ^USD	-14,36%		-15,40%	+44,59%

12/12	ARCUS BIOSCIENCES, INC. : Een koopadvies van Wedbush	ZM
12/12	ARCUS BIOSCIENCES, INC. : Truist Securities herhaalt koopadvies	ZM

Andere talen

Arcus Biosciences, Inc. Provides Update on Phase 3 Star-221 Study and Concentrates Its R&D Investment on Cas Datifan and Emerging Inflammation and Immunology Portfolio	12/12
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update	12/12
Arcus Biosciences Discontinuing Gastric, Esophogeal Cancer Candidate Trial; Shares Fall	12/12
Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment	12/12
Arcus scraps late-stage cancer trial after weak survival data	12/12
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio	12/12
Arcus Biosciences Announces New Employment Inducement Grants	10/12
Arcus Biosciences to Participate in Two Upcoming Investor Conferences	18/11
Arcus Biosciences Prices $250 Million Common Stock Offering	31/10
Arcus Biosciences says it announces pricing of $250 million public offering of common stock	31/10
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock	31/10
Arcus Biosciences Announces Commencement of Public Offering of Common Stock	30/10
Arcus Biosciences Insider Sold Shares Worth $2,010,578, According to a Recent SEC Filing	30/10
Arcus Biosciences reports third-quarter 2025 financial results and provides a pipeline update	28/10
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q3 Revenue $26.0M, vs. FactSet Est of $21.0M	28/10
Cancer drug developer Arcus Biosciences' Q3 net loss widens	28/10
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update	28/10
Arcus Biosciences, Inc. Provides Earnings Guidance for the Full Year 2025	28/10
Arcus Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	28/10
Taiho Pharmaceutical Co., Ltd. and Arcus Biosciences, Inc. Exercises Option for an Exclusive License to Cas Datifan in Japan and Certain Territories in Asia	20/10
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia	20/10
Arcus Biosciences, Inc. Announces First Overall Survival Results from Arm A1 of the Phase 2 EDGE-Gastric Study	14/10
Sector Update: Health Care Stocks Edge Lower Late Afternoon	13/10
Sector Update: Health Care Stocks Advance Monday Afternoon	13/10
Arcus - Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas	13/10

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Arcus Biosciences, Inc.

Aandelen

RCUS

US03969F1093

Biotechnologie & Medisch Onderzoek

Andere talen

Filters